Lingual Alveolar Soft Part Sarcoma in a 1-Year-Old Infant: Youngest Reported Case With Characteristic ASPSCR1-TFE3 Fusion
Abstract
Alveolar soft part sarcoma (ASPS) is an exceptionally rare non-rhabdomyosarcomatous soft tissue sarcoma (NRSTS), characterized by the translocation t(X;17) p(11.2;q25). This translocation results in the chimeric ASPSCR1-TFE3 transcription factor which drives tumorigenesis. Complete surgical resection is crucial in allowing a successful outcome in these cases. Here, we describe an 11-month-old female infant who presented with a well-circumscribed lesion of the tongue, with the clinical and radiologic appearances of an infantile hemangioma. This led to an initial plan for surveillance management. However, the mass continued to enlarge and the lesion was therefore biopsied when the infant was 17 months old. Histology showed plump epithelioid tumor cells, in many places lining pseudoalveolar spaces. Occasional Pas-D inclusions were present in the cytoplasm. Immunostaining showed nuclear positivity for TFE-3. Real-time quantitative polymerase chain reaction testing confirmed the presence of ASPSCR1-TFE3 fusion transcripts, characteristic of the translocation t(X;17) p(11.2;q25) observed in ASPS. This represents the youngest reported ASPS case with a confirmed molecular diagnosis. Complete surgical resection was undertaken and a surveillance imaging schedule implemented. This case highlights the need for regular review of the initial diagnosis and the importance of multidisciplinary discussion and early biopsy where the clinical course does not follow that expected for the putative (nonhistologically confirmed) diagnosis.
Keywords alveolar soft part sarcoma, ASPSCR1-TFE3, lingual, t(X;17) p(11.2;q25)
https://journals.sagepub.com/doi/abs/10 ... 6619830290
Lingual Alveolar Soft Part Sarcoma in a 1-Year-Old Infant: Youngest Reported Case With Characteristic ASPSCR1-TFE3 Fusio
New research, clinical trial outcomes, etc.
Return to “Medical Publications”
Jump to
- Welcome to CureASPS.org!
- ↳ Guest Book
- ↳ Forum Issues and Suggestions
- News and Updates
- ↳ Personal Stories and Updates
- ↳ Success Stories
- ↳ Rest In Peace
- ↳ Anonymous Patient Updates
- ↳ Chinese group news
- ↳ Medical Publications
- ↳ Other Publications
- ↳ Sarcoma Meetings and Conferences
- ASPS Clinical Trials
- ↳ Other Clinical Trials
- ↳ COMPLETED - ARQ 197 Clinical Trial
- ↳ COMPLETED - Dana Farber Vaccine Clinical Trial (GVAX)
- ↳ Dasatinib
- ↳ Alisertib
- ↳ Cediranib
- ↳ Anlotinib
- ↳ Immune checkpoint inhibitors (ICI)
- ↳ Axitinib and Pembrolizumab (Keytruda) in Miami, US
- ↳ TECENTRIQ (atezolizumab) by Genentech
- ↳ Pfizer's PF-06801591
- ↳ Durvalumab+Tremelimumab at MDACC
- Symptoms and Diagnostics
- ↳ Symptoms
- ↳ Scan Types and Follow-Up
- ↳ Molecular Studies
- ↳ Pathology results
- Primary Tumor Treatment
- ↳ Resection
- ↳ Treatment of Non-Resectable Primary Tumor
- ↳ Radiation
- Systemic Treatment
- ↳ TKI
- ↳ Sutent (sunitinib)
- ↳ Pazopanib
- ↳ Сabozantinib (Cometriq)
- ↳ Sorafenib
- ↳ Chemotherapy
- ↳ Metronomic chemotherapy
- ↳ Temozolomide (Temodar)
- ↳ Side effects of systemic treatments
- ↳ Interferon alpha
- ↳ Immune checkpoint inhibitors ICI (PD-1 and PD-L1 targeting drugs)
- ↳ Keytruda
- ↳ Opdivo
- ↳ TECENTRIQ (atezolizumab)
- ↳ Toxicity, problems and potentiation strategies
- ↳ Treatment response criteria and evaluation/scanning problems/rare cases
- ↳ treatment discontinuation/re-treatment
- Metastatic Disease Treatment
- ↳ Local treatment modalities
- ↳ cryoablation
- ↳ Side effects/complications of the local ablations
- ↳ Radiosurgery
- ↳ Microwave ablation
- ↳ High intensity focused ultrasound (HIFU)
- ↳ Lung Metastases
- ↳ Laser assisted surgery
- ↳ Brain Metastases
- ↳ Bone Metastases
- ↳ Other Metastases
- ↳ Abdominal Metastases
- ↳ Liver metastases
- ↳ Heart Metastases
- ↳ Spinal metastases
- ↳ Adrenal metastases
- ↳ Pancreatic metastases
- Living with ASPS
- ↳ Insurance Coverage
- ↳ Second opinion from a sarcoma center
- ↳ Finanical assistance
- ↳ Diet and lifestyle
- ↳ Related studies
- ↳ Pain management
- ↳ Travel assistance